Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Descartes-30 in ARDS and COVID-19
NCT04524962Phase 1Terminated
- Sponsor
- Cartesian Therapeutics
- Start
- Feb 2021
- Primary completion
- Sep 2022
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Descartes-30 in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19), sponsored by Cartesian Therapeutics. Primary endpoint: Adverse Events and Serious Adverse Events at 3 months. Started Feb 2021; status: terminated.
02
Drugs
Descartes-30
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04524962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04524962.